Table 3. Subgroup analyses for cohorts assessing the predictive value of BISAP ≥3 for mortality.
| Subgroups | Cohort, n | DOR (95% CI) | AUC | Cochrane-Q | P value | I2 |
|---|---|---|---|---|---|---|
| Study design | ||||||
| Prospective | 3 | 16.79 (7.08–39.82) | 0.90 | 1.23 | 0.54 | 0 |
| Retrospective | 6 | 13.59 (9.07–20.37) | 0.83 | 11.75 | 0.04 | 57.4% |
| Sample size | ||||||
| ≥ 300 | 5 | 12.49 (10.02–15.58) | 0.87 | 4.89 | 0.30 | 18.1% |
| < 300 | 4 | 21.21 (5.36–84.00) | 0.89 | 7.41 | 0.06 | 59.5% |
| Main etiology | ||||||
| Biliary | 5 | 12.29 (10.41–14.51) | 0.87 | 3.30 | 0.51 | 0 |
| Alcohol | 4 | 31.25 (8.29–117.81) | 0.91 | 6.45 | 0.09 | 53.5 |
| Location | ||||||
| USA | 4 | 12.26 (10.16–14.79) | 0.93 | 3.29 | 0.35 | 8.8% |
| Asia | 5 | 24.68 (8.35–72.99) | 0.89 | 7.72 | 0.10 | 48.2% |
| SAP% | ||||||
| ≥ 10% | 4 | 11.97 (5.32–26.94) | 0.83 | 2.66 | 0.45 | 0 |
| < 10% | 3 | 37.85 (11.61–123.35) | 0.92 | 3.16 | 0.21 | 36.8% |